INTRODUCTION
Choroiditis is the infl ammation of the choroid, the middle vascular layer of the eye. Choroiditis can be due to infectious or non-infectious causes, however, many of the cases are idiopathic. The most important causes in our environment are toxoplasmic retinochoroiditis and tubercular choroiditis. [1, 2] Other forms of choroiditis are multifocal choroiditis, sarcoid choroiditis and serpiginous choroiditis. Serpiginous choroiditis is an uncommon, usually bilateral, chronic or recurrent infl ammation of the choroid, retinal pigment epithelium and choriocapillaries of unknown etiology. [3] Several studies have demonstrated associations between serpiginous choroiditis and varying etiologies. [4] [5] [6] [7] [8] Serpiginous choroiditis starts
DISCUSSION
Study of clinical profi le of serpiginous choroiditis is essential for the clear understanding of this disease, which would help in proper management. Majority of cases were seen in men with a mean age of presentation of 30 years and this fi nding is similar to those noted in northern and southern India. [9, 10] However, it was diff erent from other studies reported elsewhere which indicated later onset of the disease. [11, 12] Bilateral involvement of eyes was seen in this study population and is similar to what was reported from southern and eastern India, [9, 13] however, it is diff erent from that reported from northern India. [10] All subjects in this study had active peripapillary serpiginous choroiditis with initial lesions around the optic nerve head, similar to other reported series. [9, 10, 13] Isolated macular involvement is not seen in this series unlike what was reported by Abrez et al. from southern India. [9] The major limitation in this study was the smaller sample size and the inclusion of only patients that presented with active choroiditis, this may explain why isolated macular Persons with healed choroiditis at presentation or less than 3 months period of follow up as recorded in the case notes were not included. Information extracted included patient's demographics including age and sex. Laterality, clinical presentation and presence of any systemic diseases were documented. Best corrected visual acuity, lens status, intraocular pressure, and funduscopic fi ndings were noted at presentation and after treatment. Type of serpiginous choriditis and activity at presentation and after treatment were recorded. Treatment modalities off ered were noted from the case records. For the purpose of statistical analysis, Snellen chart visual acuity was converted to the logarithm of the minimal angle of resolution (log MAR) value and normal visual acuity was defi ned as best-corrected visual acuity (BCVA) of 0.04 or be er. All patients had Fundus Fluorescein Angiogram (FFA) at least at their initial presentation. FFA was repeated if there was a new lesion in same or the other eye or if there was a suspicion of recurrence of the disease. Active choroiditis was defi ned as grayish, yellow cream colored lesion at the level of retinal pigment epithelium showing early central hypofl uorescence and late fuzzy hyperfl uorescence at the expanding margins on FFA. Information obtained was entered into SPSS data base for analysis. Analysis was performed using simple frequencies and cross tabulation. A P value < 0.05 was considered statistically signifi cant. Permission to conduct this study was obtained from the relevant authority of the hospital and the research complied with the principles outlined in the Helsinki declaration.
RESULTS
Seventeen eyes of 11 patients diagnosed as serpiginous choroiditis were included in the study. Eight subjects (72.7%) were males and three (27.3%) were females (M: F; 3:1). Age range at presentation was from 14 to 51 years with a mean age of 30 years (±9.95 SD). Eight subjects (72.7%) had bilateral involvement at presentation. Ten patients (90.9%) presented with complaints of diminished vision in the aff ected eye while the other patient presented with complain of seeing fl oaters in the aff ected eye as shown in Table 1 .
Visual acuity (VA) ranged from 0.00 to 1.40 at presentation. Mean VA improved to 0.34 (±0.45 SD) after treatment from 0.49 at presentation. Presence of visual impairment at presentation and after treatment is shown in Table 2 .
All 17 eyes were diagnosed as active peripapillary serpiginous choroiditis. Fourteen eyes (82.4%) had a recurrence of uveitis after the treatment with macular involvement in 5 eyes (29.4%) as in Table 1 . 
CONCLUSION
Patients with serpiginous choroidits can achieve a signifi cant visual improvement following the successful treatment with steroids and immunosuppressive treatment. We recommend early diagnosis of these cases and prompt institution of an appropriate treatment to forestall any visual impairment due to macular involvement.
involvement were not seen, even though the two studies were conducted from the same region. About one-third of the patients in this series had macular involvement at initial presentation; necessitating early diagnosis and institution of therapy. Patients were commenced on treatment after obtaining physician's clearance. Four patients were treated with oral steroids, while the remaining subjects in this series were prescribed the combination treatment (Oral prednisone 60 mg/day (1 mg/kg body weight), Oral azathioprine 50 mg three times a day, Oral cyclosporine 150 mg twice a day, with antacid and calcium supplements). On follow-up visits, the lesions heal over a period of 3 months, and the treatment is gradually tapered. Following this modality of treatment the lesions healed in all eyes with active serpiginous choroiditis at presentation except in one patient where anti-tuberculous treatment was instituted as suggested by quantiFERON TB gold test and High-resolution computed tomographic scan (HRCT) of the chest. There was no signifi cant diff erence in the rate of recurrence among patients treated with oral steroid alone and those treated with combination therapy (P = 0.308). This is in keeping with the study by Abrez et al. from southern India. [9] The presentation of serpiginous choroiditis is noted to vary across diff erent study populations, and there is a need for increased reporting of cases for the be er understanding of this disease. [10] The current treatment protocol for serpiginous choroiditis also remains controversial. [14, 15] Although oral steroid remain the mainstay, there is often a need for immunosuppressive in view of non-response, recurrence, or steroid-induced side eff ects. [9, 10, 14, 15] Antituberculous therapy was used in one patient in this series due to non-healing of the lesions after 3 months of instituting treatment and evidence of tuberculosis from a positive quantiFERON TB Gold test and HRCT chest.
Visual impairment signifi cantly improved following successful treatment of serpiginous choroiditis in this study (P = 0.002). Patients with macular involvement had moderate to severe visual impairment (P < 0.001). Recurrences that were successfully treated did not show signifi cant visual impairment after treatment (P = 0.305). It is important to mention that this study provides the profi le of a uveitic disease as is seen in a clinic in India. A similar study could be performed on uveitic disease within Africa and contrasted with fi ndings from India and other regions of the world. 
